Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction;Ostry zawał serca - Pierwotna angioplastyka: Przeciwpłytkowy efekt nowego schematu podawania tirofibanu

Kardiologia Polska

Volumn 60, Issue 5, 2004, Pages 459-467

  Kralisz, Paweł ^a,b   Dobrzycki, Sławomir ^a,b   Nowak, Konrad ^a,b   Kochman, Wacław ^a,b   Gajewska Bachórzewska, Hanna ^a,b   Gugała, Kamil ^a,b   Mȩzyński, Grzegorz ^a,b   Prokopczuk, Przemysław ^a,b   Zuk, Jerzy ^a,b   Korecki, Janusz ^a,c   Poniatowski, Bogusław ^a,b   Musiał, Włodzimierz ^a,c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Zaklad Kardiologii Inwazyjnej SPSK   (Poland)

^c Klinika Kardiologii   (Poland)

Author keywords

Acute myocardial infarction; Platelet inhibition; Primary angioplasty; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BOLUS INJECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DOSE RESPONSE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; MALE; MORTALITY; PLATELET AGGREGATION UNIT; RAPID PLATELET FUNCTION ASSAY; RECURRENT DISEASE; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

EID: 2642568728     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Brener S.J., Barr L.A., Burchenal J.E.B. et al.: for RAPPORT Investigators. Randomised, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998, 98, 734-41.
2. Montalescot G., Barragan P., Wittenberg O. et al.: Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: the ADMIRAL study, 30 day results. Eur. Heart J. 1999, 20 (suppl), 170.
3. Stone G., Grines C.L., Cox D.A. et al.: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. The CADILLAC study. N. Engl. J. Med. 2002, 346, 957-66.
4. Van den Merkhof L.F.M., Zijlstra F., Olsson H. et al.: Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty - results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J. Am. Coll. Cardiol. 1999, 33, 1528-1532.
5. Cutlip D.E., Cove C.J., Irons D. et al.: Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am. J. Cardiol. 2001, 88, 62-64.
6. Herrmann H.C., Moliterno D.J., Ohman E.M. et al.: Facilitation of early percutaneous intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) trial. J. Am. Coll. Cardiol. 2000, 36, 1497-9.
7. Karlheinz P., Kohler B., Straub A. et al.: Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and tiklopidine. Circulation 2000, 102, 1490-1496.
8. Lee D., Herity N.A., Hiatt B.L. et al.: Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes. Results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003, 107, 14977-1501.
9. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. 1994, 330, 956-961.
10. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous revascularisation. N. Engl. J. Med. 1997, 336, 1689-1696.
11. Tcheng J.E., Harrington R.A., Kottke-Marchant K. et al.: Multicenter, randomised, double-blind, placebo controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. IMPACT Investigators. Circulation 1995, 91, 2151-2157.
12. IMPACT II Investigators. Randomised placebo-controlled trial of the effect of integrilin on complications of PTCA: IMPACT II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997, 349, 1422-1428.
13. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997, 96, 1445-1453.
14. O'Shea J.C., Hafley G.E., Greenberg S. et al.: ESPRIT Investigators. Platelet glycoprotein IIb/IIIa inegrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomised controlled trial. JAMA 2001, 285, 2468-2473.
15. The PRISM-Plus Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N. Engl. J. Med. 1998, 338, 1488-1497.
16. Steinhubl S., Talley D., Braden G. et al. for the GOLD Study. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001, 103, 2572-2578.
17. Kabbani S., Aggarwal A., Terrien E. et al.: Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am. J. Cardiol. 2002, 89, 647-650.
18. Kereiakes D.J., Broderick T.M., Roth E.M. et al.: Time course, magnitude and consistency of platelet inhibition by abciximab, tirofiban or eptifibatide in patients with unstable angina undergoing percutaneous coronary intervention. Am. J. Cardiol. 1999, 84, 391-395.
19. Gawaz M., Neumann F.J., Ott I. et al.: Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996, 93, 229-237.
20. Topol E.J., Moliterno D.J., Herrmann H.C. et al.: TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. 2001, 344, 1888-1894.
21. Smith J., Steinhubl S., Lincoff M. et al.: Rapid Platelet-Function Assay. An automated and quantitative cartridge-based method. Circulation 1999, 99, 620-625.
22. Brown D.L., Fann C., Chang C.J.: Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am. J. Cardiol. 2001, 87, 537-541.
23. Harder S., Klinkhardt U., Graff J. et al.: In vitro dose response to different GPIIb/IIIa antagonists: inter-laboratory comparison of various platelet function tests. Thromb. Res. 2001, 102, 49-48.
24. Hjemdal P., Chronos N.A.F., Wilson D.J. et al.: Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler. Thromb. 1994, 14, 77-84.
25. Gasperetti Ch., Gonias S., Gimple L. et al.: Platelet activation during coronary angioplasty in humans. Circulation 1993, 88, 2728-2734.
26. Kabbani S.S., Watkins M.W., Ashikaga T. et al.: Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous intervention. Circulation 2001, 104, 181-186.
27. Kini A.S., Richard M., Suleman J. et al.: Effectiveness of tirofiban, Eptifibatide and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM Pilot Study). Am. J. Cardiol. 2002, 90, 526-529.
28. Newman P.J., Valentin N.: Human platelet alloantigens: recent findings, new perspectives. Thromb. Haemost. 1995, 74, 234-239.
29. Denardo S.J., Davis K.E., Reid P.R. et al.: Efficacy and safety of minimal dose (1000 units) unfractioned heparin with abciximab in percutaneous coronary intervention. Am. J. Cardiol. 2003, 91, 1-5.